SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ADPT

Adaptive Biotechnologies Corp (NASDAQ:ADPT)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$27.93-$0.12 (-0.43%)
 
Market cap
$4.52B
Insider Score
Health Score
Analyst consensus
Listed since
Jun 27, 2019
Market Cap$4.52B+36.5%
Revenue (ttm)$298.01M+17.9%
Net Income-$70.52M+11.4%
EPS-$0.45+16.5%
Shares Out161.88M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,483,141
Open$27.43
Previous Close$28.05
Day's Range$27.15 - $28.23
52-Week Range$12.00 - $32.21
Beta2.15
AnalystsBuy
Price Target$31.58(+13.07%)
Earnings DateFeb 4, 2027

About ADPT

Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.

Address
1165 Eastlake Avenue East, Seattle, WA, 98109, US
Market Cap
4.52 billion
Employees
624
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$3.08M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
3 Buy1 Hold0 SellAvg target $25.50 (-8.7%)

4 firms rating ADPT in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From ADPT’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-0.43%
5 Days
-1.17%
1 Month
+14.42%
6 Months
+101.22%
1 Year
+36.51%

$ADPT stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ADPT holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ADPT's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ADPT Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ADPT Revenue by Segment

$83.90MTotal
MRD Revenue$72.56M86.49%
Immune Medicine Revenue$11.34M13.51%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New ADPT patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ADPT from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ADPT

IWMiShares Russell 2000 ETF$119.48M
VTIVanguard Morningstar Total Stock Market ETF$101.24M
ARKGARK Genomic Revolution ETF$50.06M
VBVanguard Morningstar Small-Cap ETF$45.22M
IWOiShares Russell 2000 Growth ETF$42.13M
VXFVanguard Extended Market ETF$38.14M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ADPT’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
97
News & Sentiment
20% of score
72

News check: Analyst fair value lift and positive conference data presentation on ClonoSEQ's clinical role support bullish tone; valuation concerns are secondary.

Recent Insider Activity

Buys
0
Sells
18
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-37.0 since Aug 21
0255075100Aug 21 — Insider Score 37.0Aug 22 — Insider Score 37.0Aug 23 — Insider Score 37.0Aug 24 — Insider Score 37.0Aug 25 — Insider Score 37.0Aug 26 — Insider Score 36.0Aug 27 — Insider Score 36.0Aug 28 — Insider Score 37.0Aug 29 — Insider Score 36.0Aug 30 — Insider Score 36.0Aug 31 — Insider Score 36.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 25.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

HELXFranklin Genomic Advancements ETF5.07%
ARKGARK Genomic Revolution ETF2.84%
HTECROBO Global Healthcare Technology and Innovation ETF2.05%
GNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETF1.96%
GERMETFMG Treatments, Testing and Advancements ETF1.55%
TMATMain Thematic Innovation ETF1.54%
EKGFirst Trust Nasdaq Lux Digital Health Solutions ETF1.53%
DWASInvesco Dorsey Wright SmallCap Momentum ETF1.41%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF1.03%
FYCFirst Trust Small Cap Growth AlphaDEX Fund0.68%
CTAGCalamos Timpani Active SMID Growth ETF0.67%
ETHOAmplify Etho Climate Leadership U.S. ETF0.62%

Weight is the stock’s share of each fund’s holdings.